View Clinical Trial (Medical Research Study)

Reactions to Contrast Media (CM) Administered at the Time of the Endoscopic Retrograde Cholangiopancreatography (ERCP) - NCT00900640-32610(Clinical Trial 291865)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Gainesville
State:  
FL
Zip Code: 32610
Conditions: Contrast Allergies
Purpose: The aim of this study is to prospectively document the incidence of CM adverse reactions at the time of ERCP and to determine whether various perceived risk factors are predictive of adverse reaction. Adverse reactions to iodine containing contrast media (CM) have been described after endoscopic retrograde cholangiopancreaticography (ERCP) but have been difficult to study due to their extremely low incidence. Adverse reactions can be classified by severity (mild, moderate or severe) or underlying mechanism (idiosyncratic versus nonidiosyncratic). Nonidiosyncratic reactions are related to the dose and osmolality of the CM; these are not observed during ERCP due to the relative small amount of systemic absorption of CM. Idiosyncratic reactions on the other hand are not dose-dependent and generally occur shortly after administration of CM. Premedication with corticosteroids, H1/H2 -blockers and the use of low osmolality CM is beneficial in preventing nonidiosyncratic reactions during intravascular administration. However their role in during ERCP is unclear as CM is not injected into the intravascular space. Currently there are no formal recommendations and clinical practice varies considerably. The general purpose of this study is to determine the incidence of CM reactions during ERCP and to determine whether various risk factors are predictive of idiosyncratic reactions. Based on these results, we hope to develop guidelines for the use of prophylaxis to prevent CM reactions in ERCP.
Study summary:
Criteria: Inclusion Criteria: 1. Age 18 years or older. 2. Scheduled to undergo ERCP at the University of Florida, Gainesville, FL 3. History of prior reaction to IV CM and/or shellfish allergy 4. Subject must be able to give informed consent Exclusion Criteria: 1. Any contraindication to performing ERCP. 2. Participation in another research protocol that could interfere or influence the outcomes measures of the present study. 3. The subject is unable/unwilling to give informed consent.
Study is available at: Shands UF endoscopy Center
Gainesville, FL 32610
United States

Primary Contact:
Peter V Draganov, MD
Email: peter.draganov@medicine.ufl.edu
Phone: 352-392-2877

Secondary Contact:
Peter V Draganov, MD
Email: peter.draganov@medicine.ufl.edu
Phone: 352-392-2877
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.